Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $110.76 -0.18 (-0.16%) 8:16 AM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.94 USD
+1.05 (0.96%)
Updated Aug 15, 2024 04:00 PM ET
Pre-Market: $110.76 -0.18 (-0.16%) 8:16 AM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Manufacturing Numbers Expected After Opening Bell
by Zacks Equity Research
Manufacturing Numbers Expected After Opening Bell.
Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.
Q4 Earnings Roundup: ABT, GD, KMB & More
by Mark Vickery
A spot-check of early morning Q4 reports show some earnings misses and revenue beats; Tesla and others report after the close.
Here's What Key Metrics Tell Us About Abbott (ABT) Q4 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Q4 Earnings Match Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Top Stocks to Watch as Earnings Approach
by Shaun Pruitt
Several expansive companies are expected to post stellar quarterly growth when they report Q4 results on Wednesday, January 24.
What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
Should You Buy Abbott Laboratories (ABT) Ahead of Earnings?
by Zacks Equity Research
Abbott Laboratories (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.
Seeking Clues to Abbott (ABT) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
If You Invested $1000 in Abbott 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $114.02, signifying a +0.08% move from its prior day's close.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay
by Zacks Equity Research
Abbott (ABT) is successfully continuing the rollout of Alinity, the company's fully integrated and automated molecular diagnostics analyzer.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories, Qualcomm, Morgan Stanley and Intuitive Surgical
by Zacks Equity Research
Advanced Micro Devices, Abbott Laboratories, Qualcomm, Morgan Stanley and Intuitive Surgical are included in this Analyst Blog.
Top Analyst Reports for AMD, Abbott Laboratories & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Advanced Micro Devices, Inc. (AMD), Abbott Laboratories (ABT) and QUALCOMM Incorporated (QCOM).
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $113.92, representing a +0.37% change from its previous close.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott (ABT) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Abbott (ABT) closed at $112.73 in the latest trading session, marking a +0.29% move from the prior day.
Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.
3 Dividend Growers Suited for Income Investors
by Derek Lewis
A company's ability to consistently pay and increase dividend payouts reflects a stable and healthy financial position. Who doesn't enjoy payday?
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
Wearable Technology Market Gains Ground, 3 Stocks in Focus
by Moumi Mondal
In the wearable medical devices industry, investors can keep a keen eye on stocks such as ABT, MDT and DXCM.